Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Leuprorelin | Degarelix |
|---|---|---|
| Class | GnRH agonist | GnRH antagonist |
| Research category | oncology, gynaecology and precocious puberty | urological oncology |
| Evidence level | High | High |
| Overall status | Approved (Rx) — prostate cancer, endometriosis, central precocious puberty | Approved (Rx) — advanced prostate cancer |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Approved (Rx) |
| WADA | Prohibited in males — S2 | Check current list |
| Mechanism studied | Leuprorelin → GnRH receptor → Initial flare → desensitisation → Sex steroids ↓ | Degarelix → GnRH receptor blockade → LH & FSH ↓ → Testosterone ↓ |
| Molecular weight | 1,209.4 g/mol | 1,632.3 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Endocrine research. Leuprorelin is classed as gnrh agonist, while Degarelix is gnrh antagonist. Evidence is rated high for Leuprorelin and high for Degarelix.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.